Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Novartis, Alnylam to Work Together to Develop Liver Medicine

Jan. 6, 2022, 8:11 AM

Novartis AG agreed to work with Alnylam Pharmaceuticals Inc. to develop a treatment that can restore liver function and offer an alternative to transplants.

The U.S. biotech company’s technology will be used to inhibit a target identified by Novartis researchers, the Swiss company said Thursday, without disclosing financial details.

Alnylam, which turned a Nobel Prize-winning concept called RNA interference into treatments for rare genetic conditions, has been a subject of takeover speculation. Novartis, having just sold a $21 billion stake in rival Roche Holding AG, could use the cash to buy a biotech and Alnylam has been on the potential ...